Joshua J Gagne1, Melinda C Power. 1. Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA. jgagne1@partners.org
Abstract
BACKGROUND/ OBJECTIVE: Anti-inflammatory drugs may prevent Parkinson disease (PD) by inhibiting a putative underlying neuroinflammatory process. We tested the hypothesis that anti-inflammatory drugs reduce PD incidence and that there are differential effects by type of anti-inflammatory, duration of use, or intensity of use. METHODS: MEDLINE and EMBASE were searched for studies that reported risk of PD associated with anti-inflammatory medications. Random-effects meta-analyses were used to pool results across studies for each type of anti-inflammatory drug. Stratified meta-analyses were used to assess duration- and intensity-response. RESULTS: Seven studies were identified that met the inclusion criteria, all of which reported associations between nonaspirin nonsteroidal anti-inflammatory drugs (NSAIDs) and PD, 6 of which reported on aspirin, and 2 of which reported on acetaminophen. Overall, a 15% reduction in PD incidence was observed among users of nonaspirin NSAIDS (relative risk [RR] 0.85, 95% confidence interval [CI] 0.77-0.94), with a similar effect observed for ibuprofen use. The protective effect of nonaspirin NSAIDs was more pronounced among regular users (RR 0.71, 95% CI 0.58-0.89) and long-term users (RR 0.79, 95% CI 0.59-1.07). No protective effect was observed for aspirin (RR 1.08, 95% CI 0.92-1.27) or acetaminophen (RR 1.06, 95% CI 0.87-1.30). Sensitivity analyses found results to be robust. CONCLUSIONS: There may be a protective effect of nonaspirin nonsteroidal anti-inflammatory drug use on risk of Parkinson disease (PD) consistent with a possible neuroinflammatory pathway in PD pathogenesis.
BACKGROUND/ OBJECTIVE: Anti-inflammatory drugs may prevent Parkinson disease (PD) by inhibiting a putative underlying neuroinflammatory process. We tested the hypothesis that anti-inflammatory drugs reduce PD incidence and that there are differential effects by type of anti-inflammatory, duration of use, or intensity of use. METHODS: MEDLINE and EMBASE were searched for studies that reported risk of PD associated with anti-inflammatory medications. Random-effects meta-analyses were used to pool results across studies for each type of anti-inflammatory drug. Stratified meta-analyses were used to assess duration- and intensity-response. RESULTS: Seven studies were identified that met the inclusion criteria, all of which reported associations between nonaspirin nonsteroidal anti-inflammatory drugs (NSAIDs) and PD, 6 of which reported on aspirin, and 2 of which reported on acetaminophen. Overall, a 15% reduction in PD incidence was observed among users of nonaspirin NSAIDS (relative risk [RR] 0.85, 95% confidence interval [CI] 0.77-0.94), with a similar effect observed for ibuprofen use. The protective effect of nonaspirin NSAIDs was more pronounced among regular users (RR 0.71, 95% CI 0.58-0.89) and long-term users (RR 0.79, 95% CI 0.59-1.07). No protective effect was observed for aspirin (RR 1.08, 95% CI 0.92-1.27) or acetaminophen (RR 1.06, 95% CI 0.87-1.30). Sensitivity analyses found results to be robust. CONCLUSIONS: There may be a protective effect of nonaspirin nonsteroidal anti-inflammatory drug use on risk of Parkinson disease (PD) consistent with a possible neuroinflammatory pathway in PD pathogenesis.
Authors: Honglei Chen; Eric Jacobs; Michael A Schwarzschild; Marjorie L McCullough; Eugenia E Calle; Michael J Thun; Alberto Ascherio Journal: Ann Neurol Date: 2005-12 Impact factor: 10.422
Authors: Omer Aziz; Vasilis Constantinides; Paris P Tekkis; Thanos Athanasiou; Sanjay Purkayastha; Paraskevas Paraskeva; Ara W Darzi; Alexander G Heriot Journal: Ann Surg Oncol Date: 2006-02-01 Impact factor: 5.344
Authors: Andra L Blomkalns; Anita Y Chen; Judith S Hochman; Eric D Peterson; Kelly Trynosky; Deborah B Diercks; Gerard X Brogan; William E Boden; Matthew T Roe; E Magnus Ohman; W Brian Gibler; L Kristin Newby Journal: J Am Coll Cardiol Date: 2005-03-15 Impact factor: 24.094
Authors: Thanh G Ton; Susan R Heckbert; W T Longstreth; Mary Anne Rossing; Walter A Kukull; Gary M Franklin; Phillip D Swanson; Terri Smith-Weller; Harvey Checkoway Journal: Mov Disord Date: 2006-07 Impact factor: 10.338
Authors: Lisa M Kosloski; Duy M Ha; Jessica A L Hutter; David K Stone; Michael R Pichler; Ashley D Reynolds; Howard E Gendelman; R Lee Mosley Journal: J Neurochem Date: 2010-05-26 Impact factor: 5.372
Authors: David Sulzer; Angelo Antonini; Valentina Leta; Anna Nordvig; Richard J Smeyne; James E Goldman; Osama Al-Dalahmah; Luigi Zecca; Alessandro Sette; Luigi Bubacco; Olimpia Meucci; Elena Moro; Ashley S Harms; Yaqian Xu; Stanley Fahn; K Ray Chaudhuri Journal: NPJ Parkinsons Dis Date: 2020-08-20
Authors: Stefka Gyoneva; Lauren Shapiro; Carlos Lazo; Ethel Garnier-Amblard; Yoland Smith; Gary W Miller; Stephen F Traynelis Journal: Neurobiol Dis Date: 2014-03-13 Impact factor: 5.996
Authors: Andreas Puschmann; Christophe Verbeeck; Michael G Heckman; Alexandra I Soto-Ortolaza; Timothy Lynch; Barbara Jasinska-Myga; Grzegorz Opala; Anna Krygowska-Wajs; Maria Barcikowska; Ryan J Uitti; Zbigniew K Wszolek; Owen A Ross Journal: Parkinsonism Relat Disord Date: 2011-04-11 Impact factor: 4.891